Download MendeleyOptimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors.
Goldberg, D.R., De Lombaert, S., Aiello, R., Bourassa, P., Barucci, N., Zhang, Q., Paralkar, V., Stein, A.J., Holt, M., Valentine, J., Zavadoski, W.(2017) Bioorg Med Chem Lett 27: 413-419
- PubMed: 28041831
- DOI: https://doi.org/10.1016/j.bmcl.2016.12.053
- Primary Citation of Related Structures:
5L01, 5TPG - PubMed Abstract:
As a follow-up to the discovery of our spirocyclic proline-based TPH1 inhibitor lead, we describe the optimization of this scaffold. Through a combination of X-ray co-crystal structure guided design and an in vivo screen, new substitutions in the lipophilic region of the inhibitors were identified. This effort led to new TPH1 inhibitors with in vivo efficacy when dosed as their corresponding ethyl ester prodrugs. In particular, 15b (KAR5585), the prodrug of the potent TPH1 inhibitor 15a (KAR5417), showed robust reduction of intestinal serotonin (5-HT) levels in mice. Furthermore, oral administration of 15b generated high and sustained systemic exposure of the active parent 15a in rats and dogs. KAR5585 was selected for further pharmacological evaluation in disease models associated with a dysfunctional peripheral 5-HT system.
Organizational Affiliation:
Karos Pharmaceuticals, 401 Winchester Ave., 5 Science Park, New Haven, CT 06511, United States. Electronic address: dgoldberg@kineta.us.
